Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain

Life Sciences

Volumn 58, Issue 18, 1996, Pages 1551-1559

  Sandrini, M ^a   Vitale, G ^a   Vergoni, A V ^a   Ottani, A ^a   Bertolini, A ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

5 HT; Brain; Triiodothyronine

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; KETANSERIN; LIOTHYRONINE; METHYSERGIDE; RADIOLIGAND; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; HIPPOCAMPUS; HYPERTHYROIDISM; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029920534     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00129-4     Document Type: Article

References (49)

1. A. VACCARI, Progress in Brain Research, G.J. Boer, M.G.P. Feenstra, M. Mirmiran, F. Swaab and F. Van Haaren (Eds.), vol.73, 71-86, Elsevier Science Publishers BV, Amsterdam (1988).
2. A.J. PRANGE, J.C. GARBUTT and P.T. LOOSEN, Psycopharmacology: the Third Generation of Progress, H.Y. Meltzer (Ed.), 629-635, Raven Press, New York (1987).
3. P.T. LOOSEN, Hormones and Depression, U. Halbreich (Ed.), 357-383, Raven Press, New York (1987).
4. G.R. GEWIRTZ, J.A. MALASPINA, J.A. HATTERER, S. FEUREISEN, D. KLEIN and J.M. GORMAN, Am. J. Psychiatry 145 1012-1014 (1988).
5. M. SANDRINI, D. MARRAMA, A.V. VERGONI and A. BERTOLINI, Life Sci. 48 659-666 (1991).
6. M. SANDRINI, D. MARRAMA, A.V. VERGONI and A. BERTOLINI, Life Sci. 51 765-770 (1992).
7. A. VACCARI, Eur. J. Pharmacol. 82 93-95 (1982).
8. C.K. ATTERWILL, Neurophannacology 20 131-144 (1981).
9. D. BROCHET, P. MARTIN, P. SOUBRIE and P. SIMON, Eur. J. Pharmacol. 112 411-414 (1985).
10. G. TUNNICLIFF, Pharmacol. Toxicol. 69 149-156 (1991).
11. R.A. GLENNON and M. DUKAT, Current Drugs: Serotonin, 1-45 (1992).
12. P.P.A. HUMPHREY, A.W. SCHMIDT, A.J. SLEIGHT and M.A. HARRINGTON, Ann. N.Y. Acad. Sci. 600 104-129 (1990).
13. P.P.A. HUMPHREY, P. HARTIG and D. HOYER, Trends Pharmacol. Sci. 14 233-236 (1993).
14. J.M. PALACIOS, C. WAEBER, G. MENGOD and M. POMPEIANO, Serotonin: Molecular biology, receptors and functional effects, R.J. Folard and P.R. Saxena (Eds.), 5-20, Birkauser Verlag, Basel (1991).
15. D. HOYER, D.E. CLARKE, J.R. FOZARD, P.R. HARTIG, G.R. MARTIN, E.J. MYLECTARANE, P.R. SAXENA and P.P.A. HUMPHREY, Pharmacol. Rev. 46 157-203 (1994).
16. F.J. MOSMA, Y. SHEN, R.P. WARD, M.W. HANBLIN and D.R. SIBLEY, Mol. Pharmacol. 43 320-327 (1993).
17. M.S. BEER, J.A. STANTON, J. BEVAN, A.J. REEVE, V.G. STREET, V.G. MATASSA, R.J. HARGREAVES and D.N. MIDDLEMISS, Br. J. Pharmacol. 110 1196-1200 (1993).
18. S. WATSON and D. GIRDLESTONE, TiPS Receptors and Ion Channels, 38-41 (1994).
19. N. ANDREWS, S. HUGG, L.E. GONZALES and S.E. FILE, Eur. J. Pharmacol. 264 259-264 (1994).
20. S.L. HANDLEY and L. SINGH, Trends Pharmacol. Sci. 7 324-328 (1986).
21. C.K. ATTERWILL, S.J. BUNN, D.J. ATKINSON, S.L. SMITH and D.L. HEAL, J. Neural Transm. 59 43-55 (1984).
22. A. GULATI and H.N. BHARGAVA, Eur. J. Pharmacol. 182 253-259 (1990).
23. J.E. LEYSEN, C.J.E. NIEMEGEERS, J.M. VAN NEUTEN and P.M. LADURON, Mol. Pharmacol. 21 301-314 (1981).
24. O.H. LOWRY, N.J. ROSENBROUGH, A.L. FARR and L.J. RANDALL, J. Biol. Chem. 193 265-275 (1951).
25. N.E. ROSENTHAL, Mol. Biochem. 20 525-532 (1967).
26. G.A. MASON, C.H. WALKER, A.J. PRANGE and S.C. BONDY, Psychoneuroendocrinology 12 53-59 (1987).
27. S. SUZUKY, T. YOSHIDA, S. SUGITA, A. KOBAYASHI and K. MAKAZAWA, Eur. J. Pharmacol. 231 297-300 (1993).
28. W.M. PARDRIDGE, Endocrinology. 105 605-612 (1979).
29. M.B. DRATMAN, M.B. CRUTHCFIELD and J.L. SCHOENHOFF, Brain Res. 554 229-236 (1990).
30. M. AZAM and N.Z. BAQUER, Biochem. Int. 20 1141-1148 (1990).
31. L.W. CHENG, L.V. Outterbridge, N.D. Covatta, D.A. Martens, Y.T. Gordon and M.B. Dratman. Neurophysiol. 72 380-391 (1994).
32. F. CHAOULOFF, Brain Res. Rev. 18 1-32 (1993).
33. D.J. HEAL and S.L. SMITH, Neuropharmacology 27 1239-1248 (1988).
34. L. UPADHYAYA, J.K. AGRAWAL and G.P. DUBEY, Exp. Clin. Endocrinol. 101 307-310 (1993).
35. G.A. MASON, S.C. BONDY, C.B. NEMEROFF, C.H. WALKER and A.J. PRANGE Jr., Psychoneuroendocrinology 12 261-270 (1987).
36. S.M. TEJANI-BUTT, J. YANG and A. KAVIANI, Neuroendocrinology 57 1011-1018 (1993).
37. L.I. BACKUS, T. SHARP and D.G. GRAHAM-SMITH, Br. J. Pharmacol. 100 793-799 (1990).
38. J. ARNT and J. HYTTEL, Eur. J. Pharmacol. 161 45-51 (1989).
39. F.K. GOODWIN, A.R. GREEN and P. JOHNSON, Br. J. Pharmacol. 83 235-242 (1984).
40. P. MARTIN, J. MASSOL, P. SOUBRIE and A.J. PUECH, Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 13 735-748 (1989).
41. L.J. SIEVER, R.S. KAHN, B.A. LAWLOR, R.L. TRESTMAN, T.H. LAWRENCE and E.F. COCCARO, Pharmacol. Rev. 43 509-525 (1991).
42. V.S. MOTTA, S. MAISONNETTE, S. MORATO, P. CASTRECHINI and M.L. BRANDAO, Psychopharmacology 107 135-139 (1992).
43. D.L.S. CELEUMANS, M.L.J.A. HOPPENBROWERS, Y.G. GELDERS and A.J.M. REYTTJENS, Phannacopsychiatry 18 303-305 (1985).
44. R.D. GIBBONS and J.M. DAVIES, Acta Psychiatr. Scand. 24 8-12 (1986).
45. J.W. MAAS, J.H. KOCSIS, C.L. BOWDEN, J.M. DAVIS, D.E. REMOND and E. ROBINS, Psychol. Med. 12 37-43 (1982).
46. S. WELNER, C. DE MONTIGNY, J. DESCROCHES, P. DESJARDINS and M. SURANYI-CADOTTE, Synapse 4 347-352 (1989).
47. J.D. AMSTERDAM, Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 16 271-280 (1992).
48. J. COWEN, Pharmacol. Therap. 46 43-49 (1990).
49. A.S. PERUMAL, U. HALBREICH and A.I. BARKAI, Neurosci. Lett. 48 217-221 (1984).